Liraglutide

Your safety is our first priority. Learn more about key medication details, side effects, and other important info about your treatment.

Prescribing information
Common Side effects

  • Nausea

  • Diarrhea

  • Vomiting

  • Injection site reactions

  • Constipation

  • Abdominal pain

  • Upper abdominal pain

  • Increased lipase

  • Headache

  • Pyrexia

  • Fatigue

  • Dyspepsia

  • Dizziness

  • Hypoglycemia

  • Gastroenteritis

Important safety information

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as:

  • an adjunct to diet and exercise for chronic weight management.

Limitations of Use:

  • Co-administration with other liraglutide-containing products or any other GLP-1 receptor agonist is not recommended.

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning.

  • In both genders of rodents, liraglutide causes thyroid C-cell tumors at clinically relevant exposures. It is unknown whether liraglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined

  • Liraglutide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors.

Do not use Liraglutide if you:

  • Have a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2).

  • Have been diagnosed with Diabetes (Type 1)

  • Have been diagnosed with pancreatitis or history of pancreatitis

  • Have severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems with digesting food

  • Have a known allergy to liraglutide/any other GLP-1 drug or any of the inactive ingredients in liraglutide. Inactive ingredients include: Phenol, Propylene Glycol, Water, and Sodium Phosphate (Dibasic, Dihydrate).

  • Have a history of suicidal attempts or active suicidal ideation

  • Are pregnant, breastfeeding, or plan to breastfeed

WARNINGS AND PRECAUTIONS

  • Acute Pancreatitis: Discontinue promptly if pancreatitis is suspected. Do not restart if pancreatitis is confirmed.

  • Acute Gallbladder Disease: If cholelithiasis is suspected, gallbladder studies and clinical follow-up are indicated.

  • Hypoglycemia: Concomitant use with an insulin secretagogue (e.g. a sulfonylurea) or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. Reducing the dose of insulin secretagogue or insulin may be necessary. Inform all patients of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.

  • Renal Impairment: Has been reported, usually in patients reporting severe adverse gastrointestinal reactions (nausea, vomiting, diarrhea), or in those with renal impairment reporting severe adverse gastrointestinal reactions.

  • Hypersensitivity Reactions: Severe allergic reactions, including anaphylaxis and angioedema, have been reported postmarketing. Discontinue liraglutide if suspected and promptly seek medical advice.

  • Pregnancy: Weight loss during pregnancy offers no potential benefit to a pregnant woman, and may result in fetal harm. When pregnancy is desired, or recognized, discontinue liraglutide immediately.

  • Heart Rate Increase: Monitor heart rate at regular intervals.

  • Suicidal Behavior and Ideation: Monitor for depression or suicidal thoughts. Discontinue liraglutide if symptoms develop.

  • Pulmonary Aspiration During General Anesthesia or Deep Sedation: Has been reported in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures. Instruct patients to inform healthcare providers of any planned surgeries or procedures.

Side Effects Most common side effects (incidence ≥ 5%) are: nausea, diarrhea, vomiting, injection site reactions, constipation, abdominal pain, upper abdominal pain, increased lipase, headache, pyrexia, fatigue, dyspepsia, dizziness, hypoglycemia, and gastroenteritis.

To report SUSPECTED ADVERSE REACTIONS, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

DRUG INTERACTIONS Liraglutide delays gastric emptying. May impact absorption of concomitantly administered oral medications. Use with caution.